HDAC8 and idiopathic pulmonary arterial hypertension: Importantly, our in vitro and ex vivo studies suggest that isoform-selective targeting of HDAC8 may perhaps be a potential therapeutic target due to the selective upregulation of HDAC8 in the remodeled pulmonary vasculature of IPAH patients, IPAH-PAAFs and upon hypoxic exposure, while reduction of HDAC8 levels attenuated hyperproliferative phenotype of IPAH-PAAFs ex vivo.